2023 Was a troublesome 12 months for that biopharma sector, with a number of companies downsizing and restructuring their workforces to remain afloat. There are actually signs of Restoration, as mergers and acquisitions picked up throughout the pharmaceutical and lifetime sciences marketplace while in the latter A part of 2023 https://sites.google.com/view/bio-sites/blog